# Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD

> **NCT03247517** · PHASE3 · COMPLETED · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 310 (actual)

## Conditions studied

- ADHD

## Interventions

- **DRUG:** Placebo
- **DRUG:** 200mg SPN-812
- **DRUG:** 400mg SPN-812

## Key facts

- **NCT ID:** NCT03247517
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-02
- **Primary completion:** 2018-10-17
- **Final completion:** 2018-10-17
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2021-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03247517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03247517, "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03247517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*